Gershenson D - Search Results

1

Sex cord-stromal tumors of the ovary: road map for progress.

Hillman RT, Gershenson D. Hillman RT, et al. Among authors: gershenson d. Int J Gynecol Cancer. 2021 Feb;31(2):169-170. doi: 10.1136/ijgc-2020-002329. Epub 2021 Jan 12. Int J Gynecol Cancer. 2021. PMID: 33436449 No abstract available.

2

Mucinous carcinoma of the ovary. Pathologic prognostic factors.

Watkin W, Silva EG, Gershenson DM. Watkin W, et al. Among authors: gershenson dm. Cancer. 1992 Jan 1;69(1):208-12. doi: 10.1002/1097-0142(19920101)69:1<208::aid-cncr2820690134>3.0.co;2-k. Cancer. 1992. PMID: 1309304

3

Management of early ovarian cancer: germ cell and sex cord-stromal tumors.

Gershenson DM. Gershenson DM. Gynecol Oncol. 1994 Dec;55(3 Pt 2):S62-72. Gynecol Oncol. 1994. PMID: 7530680 Review.

4

Chemotherapy of ovarian germ cell tumors and sex cord stromal tumors.

Gershenson DM. Gershenson DM. Semin Surg Oncol. 1994 Jul-Aug;10(4):290-8. doi: 10.1002/ssu.2980100410. Semin Surg Oncol. 1994. PMID: 8091071 Review.

5

Treatment of poor-prognosis sex cord-stromal tumors of the ovary with the combination of bleomycin, etoposide, and cisplatin.

Gershenson DM, Morris M, Burke TW, Levenback C, Matthews CM, Wharton JT. Gershenson DM, et al. Obstet Gynecol. 1996 Apr;87(4):527-31. doi: 10.1016/0029-7844(95)00491-2. Obstet Gynecol. 1996. PMID: 8602303 Clinical Trial.

6

Serous borderline tumors of the ovary with noninvasive peritoneal implants.

Gershenson DM, Silva EG, Tortolero-Luna G, Levenback C, Morris M, Tornos C. Gershenson DM, et al. Cancer. 1998 Nov 15;83(10):2157-63. doi: 10.1002/(sici)1097-0142(19981115)83:10<2157::aid-cncr14>3.0.co;2-d. Cancer. 1998. PMID: 9827720

7

The activity of taxanes in the treatment of sex cord-stromal ovarian tumors.

Brown J, Shvartsman HS, Deavers MT, Burke TW, Munsell MF, Gershenson DM. Brown J, et al. J Clin Oncol. 2004 Sep 1;22(17):3517-23. doi: 10.1200/JCO.2004.12.074. J Clin Oncol. 2004. PMID: 15337800

8

Third-line chemotherapy in platinum- and paclitaxel-resistant ovarian, fallopian tube, and primary peritoneal carcinoma patients.

Tangjitgamol S, See HT, Manusirivithaya S, Levenback CF, Gershenson DM, Kavanagh JJ. Tangjitgamol S, et al. Among authors: gershenson dm. Int J Gynecol Cancer. 2004 Sep-Oct;14(5):804-14. doi: 10.1111/j.1048-891X.2004.014512.x. Int J Gynecol Cancer. 2004. PMID: 15361188

9

Retrospective review: re-treatment of patients with ovarian cancer with carboplatin after platinum resistance.

See HT, Freedman RS, Kudelka AP, Burke TW, Gershenson DM, Tangjitgamol S, Kavanagh JJ. See HT, et al. Among authors: gershenson dm. Int J Gynecol Cancer. 2005 Mar-Apr;15(2):209-16. doi: 10.1111/j.1525-1438.2005.15205.x. Int J Gynecol Cancer. 2005. PMID: 15823101 Free article.

10

The activity of taxanes compared with bleomycin, etoposide, and cisplatin in the treatment of sex cord-stromal ovarian tumors.

Brown J, Shvartsman HS, Deavers MT, Ramondetta LM, Burke TW, Munsell MF, Gershenson DM. Brown J, et al. Gynecol Oncol. 2005 May;97(2):489-96. doi: 10.1016/j.ygyno.2005.01.011. Gynecol Oncol. 2005. PMID: 15863149

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

511 results

Search Page